Domestic Firms Play Oral Antiviral Catchup As China Approves Paxlovid
With home-grown 3CL protease inhibitors for COVID-19 still shrouded in uncertainty, some companies in China are now turning to oral RNA polymerase inhibitors as a nearer term option for both mild-to-moderate and severe patients.
You may also be interested in...
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
While new oral COVID-19 drugs are commanding the headlines, a little-known Chinese biotech is pushing ahead with an intravenous small molecule antiviral candidate now moving towards Phase II/III US trials, its CEO tells Scrip.
Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.